Novo Nordisk and Eli Lilly Compete in Oral Weight Loss Drug Market
Eli Lilly (LLY) and Novo Nordisk (NVO) are competing for leadership in the growing weight loss drug market, with both recently receiving approval for oral versions of their GLP-1 drugs. Analysts expect this sector to reach nearly $100 billion by the end of the decade.
Topics: Eli Lilly GLP-1 drugs market share Novo Nordisk weight loss medications